The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Jane Walsh

doi:10.1158/1538-7445.SABCS16-OT3-04-03

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Jane Walsh

Psychology

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Other Item
Volume	77
DOIs	https://doi.org/10.1158/1538-7445.SABCS16-OT3-04-03
Publication status	Published - 1 Feb 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1538-7445.SABCS16-OT3-04-03

Cite this

@misc{eabdfa0e8f684ae481949a50a480da62,

title = "The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland",

author = "Jane Walsh",

year = "2017",

month = feb,

day = "1",

doi = "10.1158/1538-7445.SABCS16-OT3-04-03",

language = "English (Ireland)",

volume = "77",

type = "Other",

}